Technical Analysis for IBIO - iBio, Inc.

Grade Last Price % Change Price Change
C 4.01 19.34% 0.65
IBIO closed up 192.17 percent on Wednesday, March 27, 2024, on 48.64 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 19.34%
Crossed Above 50 DMA Bullish 19.34%
MACD Bullish Centerline Cross Bullish 19.34%
MACD Bullish Signal Line Cross Bullish 19.34%
Expansion Breakout Bullish Swing Setup 19.34%
Expansion Pivot Buy Setup Bullish Swing Setup 19.34%
Pocket Pivot Bullish Swing Setup 19.34%
Volume Surge Other 19.34%
Wide Range Bar Range Expansion 19.34%
Parabolic Rise Strength 19.34%

   Recent Intraday Alerts

Alert Time
2x Volume Pace about 1 hour ago
1.5x Volume Pace about 1 hour ago
3x Volume Pace about 1 hour ago
10x Volume Pace about 1 hour ago
5x Volume Pace about 1 hour ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

iBio, Inc. Description

iBio, Inc., a biotechnology company, engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary iBioLaunch platform technology in the United States. Its product portfolio includes seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus. The company also offers biodefense products, including oral anthrax booster vaccine candidates and candidate plague vaccines. In addition, it provides therapeutic protein product candidates comprising human alpha-galactosidase A for the treatment of Fabry disease; human C-1 esterase inhibitor for the treatment of hereditary angioedema; and human alpha-1 antitrypsin for treatment of disorders caused by a deficiency of alpha-1 antitrypsin. Further, the company offers vaccine enhancements through its iBioModulator platform. It has a license and collaboration agreement with Caliber Biotherapeutics, LLC for the development and production of recombinant plant-based biopharmaceuticals. The company is headquartered in Newark, Delaware.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Disorders Influenza Vaccines Vaccination Viruses Platform Technology Microbiology Angioedema Hereditary Angioedema Biodefense Influenza Vaccine Defense Products Seasonal Influenza Deficiency Fabry Disease Anthrax Avian Influenza Human Papilloma Virus Influenza Viruses Treatment Of Fabry Disease

Is IBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.4899
52 Week Low 0.2
Average Volume 3,466,116
200-Day Moving Average 0.79
50-Day Moving Average 1.20
20-Day Moving Average 1.26
10-Day Moving Average 1.31
Average True Range 0.25
RSI (14) 94.29
ADX 20.56
+DI 84.78
-DI 3.29
Chandelier Exit (Long, 3 ATRs) 3.27
Chandelier Exit (Short, 3 ATRs) 1.81
Upper Bollinger Bands 2.23
Lower Bollinger Band 0.28
Percent B (%b) 1.58
BandWidth 154.76
MACD Line 0.16
MACD Signal Line 0.01
MACD Histogram 0.1434
Fundamentals Value
Market Cap 6.74 Million
Num Shares 2.01 Million
EPS -35.00
Price-to-Earnings (P/E) Ratio -0.10
Price-to-Sales 47.32
Price-to-Book 0.18
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.96
Resistance 3 (R3) 5.89 4.96 5.52
Resistance 2 (R2) 4.96 4.30 4.99 5.38
Resistance 1 (R1) 4.16 3.89 4.56 4.23 5.23
Pivot Point 3.23 3.23 3.43 3.26 3.23
Support 1 (S1) 2.43 2.57 2.83 2.50 1.49
Support 2 (S2) 1.50 2.16 1.53 1.34
Support 3 (S3) 0.70 1.50 1.20
Support 4 (S4) 0.77